Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THEMBA II: saRNA COVID-19 Vaccine Booster Study
NCT05370040Phase 2Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- May 2022
- Primary completion
- Mar 2024
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics, RNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AAHI-SC2 Vaccine, AAHI-SC3 in coronavirus disease 2019 (COVID-19), sponsored by ImmunityBio, Inc.. Started May 2022; status: terminated.
02
Drugs
AAHI-SC2 VaccineAAHI-SC3
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05370040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05370040.